PimoPET® Tablets
PimoPET® is a pet medication which can open up main blood vessels to the heart to reduce pressure. It can also make the heart work more efficiently and clinical studies indicate that this can increase life expectancy. This medication is commonly used to treat heart failure in dogs. Dogs may need to take this medication for the rest of their lives though improvements can usually be seen in a few days. The medication is available in different strengths for different sized animals.
PimoPET® is used mostly in dogs with defective heart valves. (Valvular insufficiency or regurgitation, often as a result of nodular endocardiosis.) If the valves in the heart fail to operate properly, blood flows back when the valves is supposed to be closed, making the heart less efficient as a pump. This also makes a whooshing sound in the heart, called a heart murmur, which vets can hear using a stethoscope. PimoPET® acts on the muscle of the heart and on blood vessel walls, helping the heart to beat more efficiently.
PimoPET® is also used to treat heart problems where the muscle has become stretched and weak (dilated cardiomyopathy). The heart muscle can contract more powerfully, improving circulation to the body tissues. Vetmedin can be used on its own, but usually one or more other drugs are used to add and increase the beneficial effects.
PimoPET® is not suitable for dogs under the age of six months and should not be given to pregnant or nursing dogs. Care should also be taken with animals suffering from conditions such as diabetes and who are already taking other medications. Your vet will be able to determine if there is a risk of interactions with any other pet medication.
PimoPET® can only be obtained with a prescription from the vet. Buying prescription pet meds online still requires a written prescription, which must be sent with the order before the drugs can be supplied.
PimoPET® is used mostly in dogs with defective heart valves. (Valvular insufficiency or regurgitation, often as a result of nodular endocardiosis.) If the valves in the heart fail to operate properly, blood flows back when the valves is supposed to be closed, making the heart less efficient as a pump. This also makes a whooshing sound in the heart, called a heart murmur, which vets can hear using a stethoscope. PimoPET® acts on the muscle of the heart and on blood vessel walls, helping the heart to beat more efficiently.
PimoPET® is also used to treat heart problems where the muscle has become stretched and weak (dilated cardiomyopathy). The heart muscle can contract more powerfully, improving circulation to the body tissues. Vetmedin can be used on its own, but usually one or more other drugs are used to add and increase the beneficial effects.
PimoPET® is not suitable for dogs under the age of six months and should not be given to pregnant or nursing dogs. Care should also be taken with animals suffering from conditions such as diabetes and who are already taking other medications. Your vet will be able to determine if there is a risk of interactions with any other pet medication.
PimoPET® can only be obtained with a prescription from the vet. Buying prescription pet meds online still requires a written prescription, which must be sent with the order before the drugs can be supplied.
Presentation
PimoPET® Tablets, containing 5.0 mg pimobendan per tablet.
Uses
For the treatment of canine congestive heart failure originating from dilated cardiomyopathy or valvular insufficiency (mitral and/or tricuspid regurgitation). When used in cases of valvular insufficiency in conjunction with frusemide the product has been shown to improve the quality of life and extend life expectancy in treated dogs. When used in a limited number of cases of dilated cardiomyopathy in conjunction with frusemide, enalapril and digoxin, the product has been shown to improve the quality of life and to extend life expectancy in treated dogs.
Dosage and administration
- < 5(kg) ¼ - ½ Tab
- 5-10(kg) ½ - 1 Tab
- 11-20(kg) 1 - 2 Tab
- 21-40(kg) 2 - 4 Tab
- 41-60(kg) 4 - 6 Ta
- > 60(kg) 6 Tab
PimoPET® Tablets should be administered orally at a dose of 0.2 mg to 0.6 mg pimobendan/kg body weight per day. The preferable daily dose is 0.5 mg pimobendan/kg bodyweight. The daily dose should be divided into two equal administrations, one half of the dose given in the morning and the other half approximately 12 hours later. Each dose should be given approximately one hour before feeding.
Determine the bodyweight accurately before prescribing to ensure administration of the correct
See dosing below.
PimoPET® 5.0 mg Tablets Dosage Guide
Bodyweight Daily Dosage: Twice daily (as described above).
Determine the bodyweight accurately before prescribing to ensure administration of the correct
See dosing below.
PimoPET® 5.0 mg Tablets Dosage Guide
Bodyweight Daily Dosage: Twice daily (as described above).
Contraindications, warnings, etc
PimoPET® Tablets should not be used in cases of hypertrophic cardiomyopathies or clinical conditions where an augmentation of cardiac output is not possible for functional or anatomical reasons (e.g. aortic stenosis). The product should only be used in dogs with cardiac insufficiency.
A moderate positive chronotropic effect and vomiting may occur in rare cases. However, these effects are dose-dependent and may be avoided by reducing the dose in these cases. In rare cases transient diarrhea, anorexia or lethargy have been observed.
In studies with rats and rabbits pimobendan had no effect on fertility and embryotoxic effects only occurred at maternotoxic doses. In rat experiments it has been shown that pimobendan is excreted into milk. Therefore, the product should only be administered to pregnant and lactating females if the expected therapeutic benefits outweigh the potential risk.
The pimobendan-induced increase in contractility of the heart is attenuated in the presence of the calcium antagonist verapamil and the β-antagonist propranolol. In pharmacological studies no interaction between the cardiac glycoside ouabain and pimobendan was detected. Do not exceed the recommended dosage.
In the case of overdose, symptomatic treatment should be initiated.
Any unused product or waste material derived from such veterinary medicinal product should be disposed of in accordance with local requirements.
For animal treatment only.
In case of accidental ingestion, seek medical advice immediately and show the package leaflet or the label to the physician. Wash hands after use. Advice to doctors: accidental ingestion, especially by a child, may lead to the occurrence of tachycardia, orthostatic hypotension, flushing of the face and headaches.
A moderate positive chronotropic effect and vomiting may occur in rare cases. However, these effects are dose-dependent and may be avoided by reducing the dose in these cases. In rare cases transient diarrhea, anorexia or lethargy have been observed.
In studies with rats and rabbits pimobendan had no effect on fertility and embryotoxic effects only occurred at maternotoxic doses. In rat experiments it has been shown that pimobendan is excreted into milk. Therefore, the product should only be administered to pregnant and lactating females if the expected therapeutic benefits outweigh the potential risk.
The pimobendan-induced increase in contractility of the heart is attenuated in the presence of the calcium antagonist verapamil and the β-antagonist propranolol. In pharmacological studies no interaction between the cardiac glycoside ouabain and pimobendan was detected. Do not exceed the recommended dosage.
In the case of overdose, symptomatic treatment should be initiated.
Any unused product or waste material derived from such veterinary medicinal product should be disposed of in accordance with local requirements.
For animal treatment only.
In case of accidental ingestion, seek medical advice immediately and show the package leaflet or the label to the physician. Wash hands after use. Advice to doctors: accidental ingestion, especially by a child, may lead to the occurrence of tachycardia, orthostatic hypotension, flushing of the face and headaches.
Pharmaceutical precautions
Do not store above 25°C.
Store in the original package tightly closed in order to protect from moisture.
Keep out of reach and sight of children.
Store in the original package tightly closed in order to protect from moisture.
Keep out of reach and sight of children.
Packaging Quantities
30 tablets or 100 tablets of 5.0 mg tablets packed in white child-resistant polypropylene bottles.
Further information
Pharmacodynamic properties
Pimobendan, a benzimidazole-pyridazinone derivative, is a non-sympathomimetic, non-glycoside inotropic substance with potent vasodilatative properties.
Pimobendan exerts its stimulatory myocardial effect by a dual mechanism of action: increase in calcium sensitivity of cardiac myofilaments and inhibition of phosphodiesterase (type III). It also exhibits a vasodilating action through an inhibitory action on phosphodiesterase III activity. The combined evidence from cell culture, laboratory animal and small studies in the target species suggests that the combination of the specific PD properties of pimobendan may reduce the progression of myocardial damage in dogs with MVD and DCM when used together with other standard therapy.
Pharmacokinetic particulars
Absorption: Following oral administration of pimobendan, the absolute biovailability of the active principle is 60 - 63 %. Since this bioavailability is considerably reduced when pimobendan is administered with food or shortly thereafter, it is recommended to treat animals approximately 1 hour before feeding.
Distribution: The volume of distribution is 2.6 l/kg, indicating that pimobendan is distributed readily into the tissues. This means plasma protein binding is 93 %.
Metabolism: The compound is oxidatively demethylated to its major active metabolite (UD-CG 212). Further metabolic pathways are phase II conjugates of UD-CG 212, in essence glucuronides and sulfates.
Elimination: The plasma elimination half-life of pimobendan is 0.4 + 0.1 hours, consistent with the high clearance of 90 + 19 ml/min/kg and a short mean residence time of 0.5 + 0.1 hours.
The main active metabolite is eliminated with a plasma elimination half-life of 2.0 + 0.3 hours. Almost the entire dose is eliminated via feces.
Pimobendan, a benzimidazole-pyridazinone derivative, is a non-sympathomimetic, non-glycoside inotropic substance with potent vasodilatative properties.
Pimobendan exerts its stimulatory myocardial effect by a dual mechanism of action: increase in calcium sensitivity of cardiac myofilaments and inhibition of phosphodiesterase (type III). It also exhibits a vasodilating action through an inhibitory action on phosphodiesterase III activity. The combined evidence from cell culture, laboratory animal and small studies in the target species suggests that the combination of the specific PD properties of pimobendan may reduce the progression of myocardial damage in dogs with MVD and DCM when used together with other standard therapy.
Pharmacokinetic particulars
Absorption: Following oral administration of pimobendan, the absolute biovailability of the active principle is 60 - 63 %. Since this bioavailability is considerably reduced when pimobendan is administered with food or shortly thereafter, it is recommended to treat animals approximately 1 hour before feeding.
Distribution: The volume of distribution is 2.6 l/kg, indicating that pimobendan is distributed readily into the tissues. This means plasma protein binding is 93 %.
Metabolism: The compound is oxidatively demethylated to its major active metabolite (UD-CG 212). Further metabolic pathways are phase II conjugates of UD-CG 212, in essence glucuronides and sulfates.
Elimination: The plasma elimination half-life of pimobendan is 0.4 + 0.1 hours, consistent with the high clearance of 90 + 19 ml/min/kg and a short mean residence time of 0.5 + 0.1 hours.
The main active metabolite is eliminated with a plasma elimination half-life of 2.0 + 0.3 hours. Almost the entire dose is eliminated via feces.
Marketing authorisation number
V/NRP/17/0046 PimoPET® 5.0 mg Tablets.
Trademark Patent No.
M-17- 699